Search company, investor...
Bar Harbor BioTechnology company logo

Bar Harbor BioTechnology

Founded Year



Unattributed | Alive

Total Raised


Last Raised

$180K | 8 yrs ago

About Bar Harbor BioTechnology

Bar Harbor Biotech is a life sciences company spun-out from The Jackson Laboratory to develop gene expression products and services. Bar Harbor Biotech's technology focuses on real-time quantitative polymerase chain reaction (PCR), an established technique for gene expression used in disease research, molecular diagnostics, drug discovery, and other fields of biology research.

Headquarters Location

18 Riverfield Road

Trenton, Maine, 04605,

United States


Missing: Bar Harbor BioTechnology's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Bar Harbor BioTechnology's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Bar Harbor BioTechnology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Bar Harbor BioTechnology is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

838 items

Latest Bar Harbor BioTechnology News

JAX spin-off lands development award

Mar 3, 2021

Bar Harbor BioTechnology said today it has received a $334,632 development award from the Maine Technology Institute to develop its human genetic profiling products. The privately held company was founded in September 2006 and plans to launch its first line of products, which will be used by scientists engaged in gene expression research, Oct. 1, 2007. MTI approved the award in June and is in the process of finalizing it, Shane Beckim, a programs associate at MTI, told Mainebiz this morning. Bar Harbor BioTechnology is a for-profit spin-off of The Jackson Laboratory in Bar Harbor.

Bar Harbor BioTechnology Frequently Asked Questions (FAQ)

  • When was Bar Harbor BioTechnology founded?

    Bar Harbor BioTechnology was founded in 2006.

  • Where is Bar Harbor BioTechnology's headquarters?

    Bar Harbor BioTechnology's headquarters is located at 18 Riverfield Road, Trenton.

  • What is Bar Harbor BioTechnology's latest funding round?

    Bar Harbor BioTechnology's latest funding round is Unattributed.

  • How much did Bar Harbor BioTechnology raise?

    Bar Harbor BioTechnology raised a total of $990K.

  • Who are the investors of Bar Harbor BioTechnology?

    Investors of Bar Harbor BioTechnology include Maine Technology Institute, Small Enterprise Growth Fund of Maine, Village Ventures, Borealis Ventures and The Jackson Laboratory.

  • Who are Bar Harbor BioTechnology's competitors?

    Competitors of Bar Harbor BioTechnology include Axxam, Sirnaomics, Dicerna Pharmaceuticals, Oceanit, MOgene LC, ZEDIRA, RealBio Technology, Nuclea Biotechnologies, Tethis Srl, Geneohm Sciences and 12 more.

Compare Bar Harbor BioTechnology to Competitors

Oceanit Logo

Oceanit creates solutions through engineering consulting in civil, coastal, and environmental engineering; information systems consulting; management consulting, including Design Thinking and scientific research.

Nuclea Biotechnologies

Nuclea Biotechnologies is a healthcare company dedicated to the development and commercialization of clinical diagnostic assays identifying gene and protein expression profiles characteristic of an individual's tumor or disease. Nuclea is committed to advancing discovery and validation of clinical test platforms that are predictive of a cancer patient\'s responsiveness to oncology therapeutics and the likelihood of disease recurrence. The Company utilizes translational medicine-based technology to refine the understanding of the biological principles underpinning human disease, enabling the discovery of disease specific biomarkers. The tests developed identify a patient\'s predictive response to a particular therapy or assess the risk of the disease developing or recurring later in life. Test results deliver valuable genetic information on the specific disease guiding treatment decisions.

MOgene LC

MOgene is a biotechnology company, focused on understanding the mechanisms of cellular and organismal toxicity of chemical compounds and applying the knowledge to improve safety and efficacy of products across life science industries. MOgene uses a systems biology approach to understand gene function in the context of biological networks, to develop assays and biomarkers for molecular diagnostic solutions that would help address toxicity issues. MOgene is an Agilent-certified gene expression service provider and aims to provide microarray services including custom design of arrays, experiment design and detailed bioinformatics analysis.

Siena Biotech

nnSiena Biotech is located in Siena in a science park on the outskirts of the city, active since the beginning of last century, which is the location of Novartis, the University of Siena and the Toscana Life Sciences Park as well. The Discovery Research Division operates in an historical building located on campus. Corporate offices, the Finance & Business Development Division and the Therapeutic Research Division are located in another newly refurbished building.

ProteoGen Bio S.r.l.

ProteoGen Bio aims to join research and market in the fields of bioinformatics and biotechnology. Established in September 2003 as a spin-off company of the University of Pisa, with its expertise in different areas, and a interdisciplinary approach, ProteoGen Bio is developing technologies for helping modern molecular biology in its multi-purpose applications: from diagnostics to biomedicine, from mass spectrometry to environmental conservation.

Replikun Biotech

Replikun Biotech is a immunotherapy company founded in March 2005. The company is focused on the development and commercialization of immunotherapies to combat infectious diseases and cancer. Replikun offers licensing and collaboration opportunities based on KUNrep Vectors, its gene delivery and expression technology. The technology is underpinned by an integrated portfolio of granted and pending patent applications which comprise the KUNrep Vectors, their pharmaceutical applications and methods of manufacture. Replikun Biotech is conducting pre-clinical studies of two products: an investigational oncology candidate and a HIV vaccine, both developed using the KUNrep Vector system.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.